Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases
CA 2404438 A1 · Owner: Kerlero De Rosbo, Nicole · Inventors: Ben-Nun, Avraham; Kerlero De Rosbo, Nicole; Sappler, Gregor Paul
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clus, ters thereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA) myasthenia gravis (MG) and , uveitis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 26, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 26, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 26, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.